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Background: Drug and multidrug-resistant Plasmodium falciparum malaria has existed in Thailand for several
decades. Furthermore, Thailand serves as a sentinel for drug-resistant malaria within the Greater Mekong sub-
region. However, the drug resistance situation is highly dynamic, changing quickly over time. Here parasite in vitro
drug sensitivity is reported for artemisinin derivatives, mefloquine, chloroquine and quinine, across Thailand.
Methods: Blood was drawn from patients infected with P. falciparum in seven sentinel provinces along Thai
international borders with Cambodia, Myanmar, Laos, and Malaysia. In vitro parasite sensitivity was tested using the
World Health Organization’s microtest (mark III) (between 1994 and 2002) and the histidine-rich protein-2 (HRP2)-
based enzyme-linked immunosorbent assay (in 2010). Following World Health Organization protocol, at least 30
isolates were collected for each province and year represented in this study. Where possible, t-tests were used to
test for significant differences.
Results: There appears to be little variation across study sites with regard to parasite sensitivity to chloroquine.
Quinine resistance appears to have been rising prior to 1997, but has subsequently decreased. Mefloquine
sensitivity appears high across the provinces, especially along the north-western border with Myanmar and the
eastern border with Cambodia. Finally, the data suggest that parasite sensitivity to artemisinin and its derivatives is
significantly higher in provinces along the north-western border with Myanmar.
Conclusions: Parasite sensitivity to anti-malarials in Thailand is highly variable over time and largely mirrors official
drug use policy. The findings with regard to reduced sensitivity to artemisinin derivatives are supported by recent
reports of reduced parasite clearance associated with artemisinin. This trend is alarming since artemisinin is
considered the last defence against malaria. Continued surveillance in Thailand, along with increased collaboration
and surveillance across the entire Greater Mekong sub-region, is clearly warranted.
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The anti-malarial drug use history and drug resistant
situation in Thailand largely mirror that of the Greater
Mekong sub-region (GMS), which consists of Cambodia,
Vietnam, Laos, Thailand, Myanmar, and Yunnan Province
of China. Drug resistance in malaria has plagued this re-
gion for decades [1-3]. Resistance to chloroquine (CQ)
emerged in the late 1950s and early 1960s. In the early
1970s sulphadoxine and pyrimethamine (S/P) became the
primary anti-malarial drug for Plasmodium falciparum in-
fection in Thailand; however, within a decade the combi-
nation was largely ineffective. The focus then turned back
to quinine (QN); however because of apparent resistance,
it needed to be reinforced with tetracycline. By 1985 mef-
loquine (MQ), in combination with S/P, became the first-
line drug for confirmed P. falciparum infection and by
1991 MQ was being used alone. However, by the late
1980s MQ was already losing its efficacy, especially along
the Thailand-Cambodia and Thailand-Myanmar borders
[3]. In 1993 Thailand began some small trials using artesu-
nate (ATS) in these areas and in 1995 ATS-MQ combin-
ation became the official standard therapy for confirmed
P. falciparum cases in regions known to have high levels
of MDR malaria (specifically along the Thai-Myanmar
and Thai-Cambodian borders) [3]. To date, artemisinin
(ART)-based combination therapies have been adopted as
the front-line drugs in most P. falciparum-endemic areas
of the world because of the global problem of multidrug
resistance [4]. In the last several years potential resistance
to ART derivatives, manifested as delayed parasite clear-
ance, has been reported along the Thailand’s border
regions with Cambodia and Myanmar [5-9]. To control
the potential spread of the resistant parasites, surveillance
efforts are heightened and a containment plan is being
deployed in this region.
The GMS has historically been a breeding ground for
drug and multidrug resistant (MDR) malaria parasites.
The reasons for emergence of drug resistance in this re-
gion are not entirely clear. One potential contributor to
the problem is loose regulation of anti-malarials in many
of the nations within the GMS, where large proportions
of the anti-malarial drugs are counterfeit or substandard
[10]. Another may be misuse of anti-malarial drugs and
poor compliance of patients to drug regimens [11]. All
these factors can lead to sub-therapeutic levels of drug
residues in the blood, a condition that favours the selec-
tion for drug resistant parasites. In addition, human mi-
gration has played a major role in mediating rapid
spread of the resistant parasites both across the GMS
and to other regions of the world [12]. For example,
there was a suggestion that MDR strains originated
along the Thai-Cambodian border and then moved,
along with migrant workers, to the Thai-Myanmar
border [3]. When MDR strains were first recognized innorth-western Thailand in early 1990s, there was a high
level of migration from the south-east to the north-west,
a pattern that seems consistent with this suggestion. Re-
gardless of the origins of drug resistance, surveillance
systems that monitor the drug resistance situation in the
GMS are imperative for malaria control efforts in this
region.
In Thailand, anti-malarial drug resistance has been
monitored over time at several sentinel sites. This paper
presents longitudinal surveillance data from in vitro tests
of drug sensitivity to four commonly used anti-malarial
drugs (ART, CQ, QN, and MQ) between 1994 and 2010
from several sentinel provinces along Thai borders. Pre-
vious studies have noted abnormally high effective con-
centration values that inhibit 50% of the parasite growth
(IC50) for MQ in north-western provinces, however re-
sistance was thought to have plateaued around the turn
of the century [3]. MQ resistance, at least in vitro, subse-
quently rose to much higher levels. Furthermore, this in-
vestigation pointed to potentially increasing resistance to
ART and its derivatives. As the last line of defence
against MDR malaria parasites, this finding is alarming
and it underlines the importance of continued drug re-
sistance surveillance.
Methods
Drug resistance monitoring sites
Longitudinal in vitro monitoring of drug sensitivity of P.
falciparum clinical isolates was conducted in Trat prov-
ince bordering Cambodia, Ranong, Mae Hong Son,
Kanchanaburi and Tak provinces along Thai-Myanmar
border, Yala province in the South, and Ubon Ratchathani
province bordering Laos (Figure 1). These sentinel sites
have been strategically selected because they historically
have been among the most malarious provinces and
border the malarious regions in neighbouring countries.
Patients and parasite samples
Drug resistance monitoring was conducted at government-
run malaria clinics in the sentinel provinces, which offer
free diagnosis and treatment to malaria patients. Adult
patients with uncomplicated P. falciparum malaria were
recruited to this study after giving written consent. This
study was conducted under the auspices of the Bureau
of Vector Borne Diseases, Ministry of Public Health,
Thailand. Infection by P. falciparum was diagnosed based
on microscopic examinations of Giemsa-stained thick and
thin blood smears, and only those samples with >2,000
asexual parasites/μl of blood were used for in vitro drug
assays. After verifying that the patients had not taken anti-
malarial drugs or antibiotics within the preceding two
weeks, 1 ml of venous blood was drawn for in vitro drug
assay. In each province in a given year, at least 30 clinical
blood samples were obtained for anti-malarial drug assays.
Myanmar
Cambodia
Figure 1 Drug resistance sentinel sites along Thai borders. Colour scheme matches that of Figure 2.
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from this study.In vitro drug sensitivity assays
In vitro drug sensitivity of fresh P. falciparum isolates
has been monitored with regards to four anti-malarial
drugs: ART, CQ, QN, and MQ. Between 1993 and 2002,
the World Health Organization microtest (mark III)
was used to test drug sensitivity [13]. The microtest
requires a parasitaemia of 1,000–80,000 parasites/μl
blood. Microtiter plates were pre-dosed with serially
diluted anti-malarial compounds and a control well
(without drug) was included for each sample. Blood
from patients was mixed with RPMI 1640, mixed with
complete medium, and dispensed into the wells of the
plates at 50 μl/well. Plates were incubated at 37°C for
24–36 h in a candle jar and thin smears were examined.
Only samples with >20% parasite matured to schizonts
in the control wells were used for data analysis.
In vitro testing was halted from 2003 – 2009 because
of reduced funding. In 2010, testing switched to the
comparatively less labour-intensive histidine-rich protein-2(HRP2)-based enzyme-linked immunosorbent assay (ELISA)
[14]. This method requires a parasitaemia of >500 parasites/
μl of blood, making it easier to enrol patients in parasite
drug sensitivity studies. As with the mark III method, plates
were pre-dosed with anti-malarial compounds. IC50 values
were calculated for each parasite isolate and each drug using
regression analysis. The commercial HRP2 assay came from
Cellabs (http://cellabs.com.au/) and pre-dosed plates were
obtained from Immunology Consultants Laboratory, Inc.
(http://www.icllab.com/).Statistical analysis
Data from individual assays for the microtest III method
were discarded after summary statistics were calculated,
making quality assurance and statistical analysis difficult
or impossible for these data. Data from the HRP2
method are preserved in digital format and will be
retained so that future analyses can be done on variance
between assays within and across laboratory sites as well
as statistical analysis on IC50 dynamics. The HRP2 data
were analysed using multiple t-tests with Bonferroni
correction.
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The national drug policy changes in Thailand have been
made based on clinical observations, parasitaemia levels
after administering anti-malarials (regardless of febrile
status), on the efficacy of anti-malarial drugs (Figure 2).
Chloroquine
When CQ became the official anti-malarial drug used in
Thailand around 1965, resistance to this drug already
existed. CQ use for P. falciparum infections has long
since been halted. These data showed that CQ IC50
values varied greatly between some provinces. In many
regions such as the eastern provinces, there was a trend
of decrease in CQ resistance (Figure 3). In contrast, CQ
IC50 values remained high or even increased in the west
(e.g., Kanchanaburi and Tak provinces) around the turn
of the century. Unfortunately, CQ sensitivity monitoring
only continued in the three western provinces bordering
Myanmar (Figure 4). In each of the provinces, the year
2010 CQ IC50 values from the HRP2 method showed a
wide range of variability. However, there were no signifi-
cant differences among the three provinces (t-test,
p-value > 0.05).
Quinine
Following decreased efficacy of S/P, QN, in combination
with tetracycline, became the official anti-malarial in the
early 1980s. It was necessary to couple this drug with
tetracycline because there was already resistance to QN
alone [15]. In vitro monitoring of QN sensitivity began
in 1993, and by this time MQ had replaced QN. These
data showed that before 1997, in vitro sensitivity to QNFigure 2 Timeline showing the official use of anti-malarials (top) and
malarials were in use prior to becoming the official anti-malarial and, there
CQ= chloroquine; SP = sulphadoxine-pyrimethamine; QNN=quinine; QNN+
*MQ+ART began being used as a standard therapy for Plasmodium falcipa
Province).was relatively unchanged in some provinces (Yala, Trat,
Ubon Ratchathani, Ranong and Kanchanaburi) or even
on the rise in other provinces (Tak and Mae Hong Son).
After 1997, there was a decreasing trend in QN IC50
values in all provinces (Figure 4). Similar to the pattern
seen in the CQ data, the QN IC50 values derived from
the HRP2 method showed great variability (Figure 4),
but no significant differences (t-test, p-value > 0.05) were
detected across the three sentinel regions in 2010.Mefloquine
MQ has been in use since the mid-1980s and by the early
1990s MQ alone was the official anti-malarial used in Thai-
land. These data showed that MQ IC50 values remained
consistently high (Figure 3), although in some provinces
(such as Tak and Mae Hong Son) there was a trend of slight
decrease in IC50 values prior to 2000. In the eastern border
area (Trat Province), MQ IC50 values remained high and
even increased in 2001. In the western border area, Tak
Province showed consistently high and potentially rising
MQ resistance throughout this time period. Data from
Kanchanaburi also showed a steady trend of increase in
IC50 values. From the 2010 data using the HRP2 method
(Figure 4), MQ IC50 values were significantly higher in
Mae Hong Son Province when compared to Ranong (p-
value= 0.0006; C.I. = 73.88, 240.20). There were several
outliers in the data from Tak that appeared much higher
than values in either Mae Hong Son or Ranong. How-
ever, the combined values from Tak Province did not
reach statistical significance when compared to either of
the two provinces.anti-malarial resistance (bottom) in Thailand. In some cases, anti-
fore, drug resistance existed prior to official use (e.g., CQ).
T = quinine + tetracycline; MQ=mefloquine; ART = artemisinin.
rum in Tak Province and the south-eastern border with Cambodia (Trat
Figure 3 Results from the microtest (mark III) drug sensitivity tests (1993–2002). Colour scheme matches that of Map 1. These data have
been collected by the Bureau of Vector Borne Diseases, Ministry of Public Health, Thailand and have not previously been reported. For each year
and province, at least 30 clinical isolates were used to calculate the average IC50. The detailed results of each assay have since been discarded,
meaning that error bars and variance between assays cannot be calculated for this component of the data.
Figure 4 Results from the HRP2 data (2010). These data have been collected by the Bureau of Vector Borne Diseases, Ministry of Public
Health, Thailand and have not previously been reported. Box plots represent the mean IC50 as well as the quartiles and 95% confidence intervals
of the data.
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ATS use began in some regions of Thailand during the
early 1990s and by 1995 ATS-MQ became the official anti-
malarial for treating uncomplicated falciparum malaria
in selected areas along the Thai-Myanmar and Thai-
Cambodian borders. From these data, most of the pro-
vinces showed relatively high sensitivity to ART (Figure 3).
However, it appeared that ART IC50 values in Trat and
Tak provinces were relatively high early on, but subse-
quently decreased during the 1990’s. In contrast, ART IC50
values in Kanchanaburi were consistently high. Data from
the HRP2 method performed in 2010 indicated that in vitro
IC50 values to dihydroartemisinin (DHA) were significantly
higher in Tak Province when compared to both Mae Hong
Son (p-value =0.0321; C.I. = 0.34, 7.15) and Ranong (p-
value=0.0032; C.I. = 1.89, 8.55) (Figure 4). After applying a
Bonferroni correction to control for multiple tests, the dif-
ference between Tak and Ranong remained significant.
Discussion
These data show that the anti-malarial drug resistance
situation in Thailand (and most likely the GMS) is dy-
namic with considerable fluctuation over time. Surveil-
lance systems in the GMS are therefore crucial for
malaria control efforts, especially with regard to the use
of anti-malarials. Since drug resistant strains appear to
have arisen in this area and subsequently spread to other
parts of the world in the past, surveillance in this area is
important not only for the immediate region but also for
the entire world. This is perhaps especially the case with
the potential for ART-resistant strains coming out of the
GMS. If ART-resistant strains were to spread to Sub-
Saharan Africa, the results could be catastrophic.
CQ was widely used globally following its introduction
after World War II. In Thailand, as in other parts of the
world, resistance quickly developed. By the late 1950s,
Thailand already experienced CQ-resistant parasites,
even before CQ was designated the official anti-malarial.
While CQ use for P. falciparum infections was discon-
tinued in Thailand during the 1970s, other parts of the
world, especially Africa, continued to use the anti-
malarial for most of the 20th century. Resistance to the
drug was widespread anywhere it was in use. Tests for
in vitro and in vivo sensitivity to CQ have subsequently
shown increased sensitivity shortly after removal of drug
pressure [16]. Furthermore, mutations that have been
associated with CQ resistance (in PfCRT and Pfmdr1)
have been shown to decrease in frequency after cessation
of CQ use [16-18]. These data indicate that in Thailand
CQ resistance has decreased in eastern provinces while
potentially rising in western Provinces (such as Tak and
Kanchanaburi). This pattern may in part be explained by
the continued use of CQ for treating Plasmodium vivax
infections. Furthermore, some research has suggestedthat mixed infections are relatively widespread and
under-diagnosed in Thailand [19]. If patients infected
with both species of malaria are diagnosed with P. vivax
and subsequently treated with CQ, this will inevitably re-
tain the CQ pressure and therefore CQ resistance in P.
falciparum.
Previous research has noted abnormally high MQ
IC50 values along the Thai-Myanmar border in the
mid-1990s [3]. Other studies in the north-western re-
gion of Thailand showed a strong correlation between
high MQ IC50 values and clinical failure rates [20].
Decreased parasite sensitivity to MQ corresponded to
increased P. falciparum gametocytaemia in the study
population [20]. However, as ACT was introduced in
the area around 1995, it appeared that parasite sensi-
tivity to MQ increased. This increase in parasite sen-
sitivity to MQ has largely been attributed to the
introduction of ART and its derivatives for P. falcip-
arum infections [20,21]. However, these data indicate
that after a decrease in IC50 values around the turn
of the century, MQ IC50 values have again begun to
rise in the north-western areas of Thailand. There is
some evidence that ART resistance may be rising in Tak
Province. In addition, at both Thai-Cambodian and Thai-
Myanmar border areas, clinical resistance to ATS-MQ has
been on the rise [3,6,22]. The fact that sensitivities to MQ
and ART family drugs are often correlated [23,24] and
ATS-MQ is the most commonly used ACT formulation in
this region suggest that MQ sensitivity needs to be con-
tinuously monitored.
These results also have broad relevance for other
regions where combination therapy is being implemen-
ted in order to combat parasite resistance to mono-
therapies. These data suggest that while combination
therapies are likely to work in the short term, parasites
may develop resistance to multiple, non-structurally
related anti-malarials over time. With regards to malaria
control efforts, this indicates a need for careful moni-
toring, proactive policies, and a multi-focused approach
that focuses on vectors, the human host, and environmental
factors in malaria transmission along with continued efforts
to find other anti-malarials.
Parasites that are resistant to QN have been reported in
Thailand since the 1980s [15]. QN was used in combin-
ation with tetracycline, and remains to be used as a sec-
ond line treatment for falciparum infection and as a
monotherapy for infections in pregnant patients [25].
These data indicate general sensitivity in parasites with
regards to QN, which is expected given its infrequent use
in the region. Some studies have indicated shared resist-
ance mechanisms between the amino-alcoholic drugs and
QN [23,25]. As such, the extensive use of MQ both alone
or in ACT suggests that continued monitoring of QN re-
sistance is strongly warranted.
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Vietnam and China, however its use is relatively new in
other parts of the GMS. In the last several years there have
been reports of potential reduced sensitivity in P. falcip-
arum with regards to ART drugs in Thailand. The first
reports concerned reduced in vivo sensitivity along the
Thai-Cambodia border and more recently, tests of in vitro
sensitivity along the Thai-Myanmar border have shown
reduced sensitivity to ART and ART derivatives [5-7,22].
This research further supports these previous findings.
While most of the sentinel provinces exhibit low ART
IC50 values, Tak (on the Myanmar border) and Trat
(along the Cambodian border) both show high, fluctuating
values (Figure 3). It is curious to note that these data indi-
cate high ART and MQ IC50 values in Tak and Trat Pro-
vinces around the same time that ATS-MQ became the
standard therapy for falciparum malaria in the same loca-
tions. It is possible that sensitivity to ART was present be-
cause the drug was already in use by populations that
frequently move across the borders to Myanmar (border-
ing Tak) and Cambodia (bordering Trat) where ART
drugs has been in use for a longer period of time. How-
ever, since testing was done by different laboratory techni-
cians, places, and times, and since there are no detailed
data on individual assays it is possible that the high ART
values in Tak and Trat represent variations in laboratory
conditions. The data also indicate that DHA IC50 values
are high in north-western Thailand and perhaps especially
in Tak Province (Figure 4). These data are more reliable
than the microtest III data, since they include results from
individual assays and have error bars for comparison
across regions. Given the importance of ART and its deri-
vatives as the last line of defence against malaria, these
findings are alarming. Careful monitoring and use of ART
family drugs is crucial for global malaria control and
eradication efforts.
There are several limitations to this study, which need to
be considered for improvement in the future. The sampling
method was not systematic, taken opportunistically from
patients seeking treatment from malaria clinics and having
high parasitaemia, and thus the samples may not represent
the overall parasite population. Direct comparison of IC50
values across sentinel provinces may be problematic be-
cause of varying laboratory assay conditions and levels of
technical training. Mixed infections, which are likely to be
much more common in the GMS than was previously
thought [19], can lead to inaccuracy in drug sensitivity test-
ing [26]. In addition, while several studies have shown a
rough correlation between in vitro tests and clinical out-
comes, the potential remains for discrepancies between the
two [27]. Nevertheless, given the limited resources (espe-
cially funding and skilled labour), in vitro tests remain an
important proxy measure for clinical outcomes (e.g., para-
sitaemia quantification) in malaria infections. The HRP2method is less labour intensive than the WHO microtest,
meaning that it can be used in a more systematic way. If
resources permit, it is ideal to test the same drugs, at least
each year, continuously over time. Furthermore, quality
control measures including keeping detailed records con-
cerning variance in assays, changing laboratory personnel,
and other laboratory conditions, should be implemented
and preserved. Finally, combination of this test with more
accurate in vitro tests of culture-adapted parasites and clin-
ical efficacy (e.g., in vivo parasitaemia over time, after the
administration of anti-malarials) data will significantly
strengthen the drug surveillance data.
Furthermore, surveillance efforts in the GMS and
Thailand must adapt to changing malaria epidemiology.
Over the last several decades, P. falciparum prevalence
has decreased markedly in Thailand, while the proportion
of P. vivax cases has increased. In general, vivax malaria
has largely been ignored in epidemiology, but researchers
have come to the realization that the so-called ‘benign ter-
tian malaria’ poses a credible threat to public health [28-30].
Yet, drug resistance surveillance for this parasite has
remained scant [29]. Although CQ remained relative effect-
ive in treating P. vivax malaria in some regions of the GMS
such as Thailand and China [31,32], cases of vivax resistance
have been recorded the GMS [33-37]. In 2010 Cambodia
began using a combination therapy (DHA-piperaquine and
primaquine) as the first line treatment for P. vivax malaria.
This points towards a demand for more close monitoring of
P. vivax resistance to commonly used anti-malarials espe-
cially CQ and potentially the need for a combination therapy
for P. vivax cases [38].
In the face of potential parasite resistance to ART and
its derivatives, several actions should be taken. Since the
border regions surrounding Thailand have historically
been the site of persistent drug resistance (which may
have subsequently spread to other parts of the world), sur-
veillance of drug resistance in this region is crucial for glo-
bal health and drug policy concerns. Currently there are
in vivo studies of drug resistance, focusing on parasite
density over time within patients that have been adminis-
tered anti-malarials, in all nations of the GMS. However,
such testing is troubled by the difficulty of following some
patients over time and not all subregions or areas within
the GMS have the manpower to conduct lengthy testing
for drug resistance. The geographical range of both
in vitro and in vivo surveillance should expand into areas
of the GMS that aren’t covered by current surveillance
efforts. A more holistic, co-ordinated approach would en-
sure better surveillance across the GMS, revealing a more
comprehensive picture of the drug resistance situation.
There should be a move towards the careful regulation of
anti-malarials and combination therapy should be used
throughout the region. Several studies have shown that
fake and substandard pharmaceuticals are widespread
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also be put into place to investigate this crucial problem.
Finally, while anti-malarials are undoubtedly important
for malaria control efforts, other modes of control should
continue to be pursued. For example studies into behav-
ioural components, environment and disease interactions,
as well as both human and vector ecology have been and
will continue to be important for malaria control efforts.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RL, WS, JP, and JS carried out laboratory procedures, including drawing
blood samples and testing parasite sensitivity to anti-malarials. Surveillance
was implemented and carried out by RL, WS, JP, and JS. DP, GY, JW, and LC
collected the raw data, did the statistical analyses, and wrote the paper. All
authors contributed to the interpretation of results, the conclusion, and
approved the final manuscript.
Acknowledgements
We would like to thank staff at the sentinel malaria clinics for conducting the
malaria drug resistance surveillance and staff at the Vector-Borne Disease
Training Center in Thailand for collecting and analysing the drug sensitivity
data. This study is partially supported by NIAID, NIH (U19AI089672).
Author details
1Department of Anthropology, The Pennsylvania State University, 409
Carpenter Building, University Park, PA 16802, USA. 2Population Research
Institute, The Pennsylvania State University, 601 Oswald Tower, University
Park, PA 16802, USA. 3Vector Borne Disease Training Center, Pra Budhabat,
Saraburi 18120, Thailand. 4Public Health, University of California, Irvine, CA
92697, USA. 5Faculty of Tropical Medicine, Mahidol University, Bangkok
10400, Thailand. 6Department of Entomology, The Pennsylvania State
University, 501 ASI Building, University Park, PA 16801, USA.
Received: 30 April 2012 Accepted: 22 July 2012
Published: 21 August 2012
References
1. Wernsdorfer WH: Epidemiology of drug resistance in malaria. Acta Trop
1994, 56:143–156.
2. Singhasivanon P: Mekong malaria. Malaria, multi-drug resistance and
economic development in the greater Mekong subregion of Southeast
Asia. Southeast Asian J Trop Med Public Health 1999, 30(Suppl 4):i–iv. 1–101.
3. Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS,
Pang L, Thimasarn K: Drug resistant malaria on the Thai-Myanmar and
Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 2001,
32:41–49.
4. Nosten F, White NJ: Artemisinin-based combination treatment of
falciparum malaria. Am J Trop Med Hyg 2007, 77:181–192.
5. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,
359:2619–2620.
6. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M,
Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M,
Hutagalung R, Maung Lwin K, Pyae Phyo A, Preechapornkul P, Imwong M,
Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F: Changes in the
treatment responses to artesunate-mefloquine on the northwestern
border of Thailand during 13 years of continuous deployment. PLoS One
2009, 4:e4551.
7. Dondorp AM, Nosten F, Yi P, Das D, Phae Phyo A, Tarning J, Maung Lwin K,
Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,
Chotivanich K, Lim P, Herdman T, Sam An S, Yeung S, Singhasivanon P, Day
NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in
Plasmodium falciparum malaria. N Engl J Med 2009, 361:455–467.
8. Pyae Phyo A, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler
Moo C, Al-Saai S, Dondorp AM, Maung Lwin K, Singhasivanon P, Day NPJ,
White NJ, Anderson TJC, Nosten F: Emergence of artemisinin-resistantmalaria on the western border of Thailand: a longitudinal study. Lancet
2012, 12:1960–1966.
9. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Pyae
Phyo A, Ler Moo C, Maung Lwin K, McGready R, Ashley E, Imwong M,
Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ, Nosten
F, Ferdig MT, Anderson TJC: A major genome region underlying
artemisinin resistance in malaria. Science 2012, 336:79–82.
10. Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S,
Chotivanich K, Mayxay M, Looareesuwan S, Farrar J, Nosten F, White NJ:
Fake artesunate in southeast Asia. Lancet 2001, 357:1948–1950.
11. Yeung S, White NJ: How do patients use antimalarial drugs? A review of
the evidence. Trop Med Int Health 2005, 10:121–138.
12. Anderson TJ, Roper C: The origins and spread of antimalarial drug
resistance: lessons for policy makers. Acta Trop 2005, 94:269–280.
13. WHO: In vitro micro-test (Mark III) for the assessment of the response of
Plasmodium falciparum to chloroquine, mefloquine, quinine, amodiaquine
sulfadoxine/pyrimethamine and artemisinin. Instruction for use of the in vitro
microtest kit (Mark III). Geneva: World Health Organization; 2001.
14. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS: A histidine-
rich protein 2-based malaria drug sensitivity assay for field use. Am J
Trop Med Hyg 2004, 71:711–714.
15. Suebsaeng L, Wernsdorfer WH, Rooney W: Sensitivity to quinine and
mefloquine of Plasmodium falciparum in Thailand. Bull World Health
Organ 1986, 64:759–765.
16. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T,
Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine
sensitivity and low prevalence of the Plasmodium falciparum
chloroquine resistance transporter gene mutation K76T following the
discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg
2003, 68:413–415.
17. Mita T, Kaneko A, Lum JK, Zungu IL, Tsukahara T, Eto H, Kobayakawa T,
Bjorkman A, Tanabe K: Expansion of wild type allele rather than back
mutation in pfcrt explains the recent recovery of chloroquine sensitivity
of Plasmodium falciparum in Malawi. Mol Biochem Parasitol 2004,
135:159–163.
18. Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X, Wellems TE:
Decreased prevalence of the Plasmodium falciparum chloroquine
resistance transporter 76 T marker associated with cessation of
chloroquine use against P. falciparum malaria in Hainan, People's
Republic of China. Am J Trop Med Hyg 2005, 72:410–414.
19. Snounou G, White NJ: The co-existence of Plasmodium: sidelights from
falciparum and vivax malaria in Thailand. Trends Parasitol 2004,
20:333–339.
20. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P,
Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F: Plasmodium
falciparum antimalarial drug susceptibility on the north-western border
of Thailand during five years of extensive use of artesunate-mefloquine.
Trans R Soc Trop Med Hyg 2000, 94:537–544.
21. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A,
McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of artesunate-
mefloquine combination on incidence of Plasmodium falciparum malaria
and mefloquine resistance in Western Thailand: a prospective study.
Lancet 2000, 356:297–302.
22. Na-Bangchang K, Ruengweerayut R, Mahamad P, Ruengweerayut K,
Chaijaroenkul W: Declining in efficacy of a three-day combination
regimen of mefloquine-artesunate in a multi-drug resistance area along
the Thai-Myanmar border. Malar J 2010, 9:273.
23. Sidhu AB, Valderramos SG, Fidock DA: pfmdr1 mutations contribute to
quinine resistance and enhance mefloquine and artemisinin sensitivity
in Plasmodium falciparum. Mol Microbiol 2005, 57:913–926.
24. Chaijaroenkul W, Wisedpanichkij R, Na-Bangchang K: Monitoring of in vitro
susceptibilities and molecular markers of resistance of Plasmodium
falciparum isolates from Thai-Myanmar border to chloroquine, quinine,
mefloquine and artesunate. Acta Trop 2010, 113:190–194.
25. Poyomtip T, Suwandittakul N, Sitthichot N, Khositnithikul R, Tan-Ariya P,
Mungthin M: Polymorphisms of the pfmdr1 but not the pfnhe-1 gene is
associated with in vitro quinine sensitivity in Thai isolates of Plasmodium
falciparum. Malar J 2012, 11:7.
26. Liu S, Mu J, Jiang H, Su XZ: Effects of Plasmodium falciparum mixed
infections on in vitro antimalarial drug tests and genotyping. Am J Trop
Med Hyg 2008, 79:178–184.
Parker et al. Malaria Journal 2012, 11:290 Page 9 of 9
http://www.malariajournal.com/content/11/1/29027. Bloland PB: Drug resistance in malaria. Geneva: World Health Organization;
2001. WHO/CDS/CSR/DRS/20014.
28. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax malaria:
neglected and not benign. Am J Trop Med Hyg 2007, 77:79–87.
29. Baird JK: Severe and fatal vivax malaria challenges 'benign tertian
malaria' dogma. Ann Trop Paediatr 2009, 29:251–252.
30. Bammigatti C, Shetty S, Shetty S, Kumar A: Benign tertian malaria–a
misnomer? Trop Doct 2011, 41:168–169.
31. Lu F, Gao Q, Chotivanich K, Xia H, Cao J, Udomsangpetch R, Cui L,
Sattabongkot J: In vitro anti-malarial drug susceptibility of temperate
Plasmodium vivax from Central China. Am J Trop Med Hyg 2011,
85:197–201.
32. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-
Bangchang K: Monitoring of clinical efficacy and in vitro sensitivity of
Plasmodium vivax to chloroquine in area along Thai Myanmar border
during 2009–2010. Malar J 2011, 10:44.
33. Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y:
Emergence of chloroquine-resistant Plasmodium vivax in Myanmar
(Burma). Trans R Soc Trop Med Hyg 1993, 87:687.
34. Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O:
Development of resistance to chloroquine by Plasmodium vivax in
Myanmar. Trans R Soc Trop Med Hyg 1995, 89:307–308.
35. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M,
Zaw T, Annerberg A, de Radigues X, Nosten F: Plasmodium vivax resistance
to chloroquine in Dawei, Southern Myanmar. Trop Med Int Health 2008,
13:91.
36. Congpoung K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W,
Pranuth Y, Cholpol S, Bualombai P: In vivo sensitivity monitoring of
chloroquine for the treatment of uncomplicated vivax malaria in four
bordered provinces of Thailand during 2009–2010. J Vector Borne Dis
2011, 48:190–196.
37. Rijken MJ, Boel ME, Russell B, Imwong M, Leimanis ML, Phyo AP,
Muehlenbachs A, Lindegardh N, McGready R, Renia L, Snounou G,
Singhasivanon P, Nosten F: Chloroquine resistant vivax malaria in a
pregnant woman on the western border of Thailand. Malar J 2011,
10:113.
38. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N,
Singhasivanon P, White NJ, Nosten F: Dihydroartemisinin-piperaquine
versus chloroquine in the treatment of Plasmodium vivax malaria in
Thailand: a randomized controlled trial. Clin Infect Dis 2011, 53:977–984.
doi:10.1186/1475-2875-11-290
Cite this article as: Parker et al.: Longitudinal in vitro surveillance of
Plasmodium falciparum sensitivity to common anti-malarials
in Thailand between 1994 and 2010. Malaria Journal 2012 11:290.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
